Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
Year: 2018
Type: article
Abstract: Background: PDR001 is a high-affinity, humanized, anti-PD-1 IgG4 antibody that blocks PD-L1 & PD-L2 binding to PD-1. A phase 2, multi-center study assessed the efficacy & safety of PDR001 in pts with nonfunctional well- & poorly-differentiated (diff) neuroendocrine neoplasms.
Source: Annals of Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, European Institute of Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hôpital Beaujon, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, City Of Hope National Medical Center, City of Hope, Beckman Research Institute, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Memorial Sloan Kettering Cancer Center, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Aichi Cancer Center, Medical University of Vienna, Centre Hospitalier Universitaire de Toulouse, Hospital Universitario Ramón y Cajal, Novartis (United States), Novartis (Switzerland), Sunnybrook Health Science Centre, Sunnybrook Hospital, Odette Cancer Centre
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898283778